Patents Assigned to UCB Biopharma SRL
  • Patent number: 12162934
    Abstract: The invention relates to an anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: December 10, 2024
    Assignees: UCB BIOPHARMA SRL, OXFORD UNIVERSITY INNOVATION LIMITED, THE UNIVERSITY OF ADELAIDE
    Inventors: Gareth Charles Glyndwr Davies, Simon Leedham, Andrew Zannettino, Kimberley Clark, Duncan Hewett, Vasilios Panagopoulos
  • Patent number: 12165316
    Abstract: A machine-based learning system for predicting the presence of lesions indicative of axial spondyloarthritis in medical imaging data includes an image processor for receiving and processing one or more MRI image data set containing pelvic region and sacroiliac joint of a subject, and dividing said MRI image data set into a set of 3D voxels. The system also includes a voxel classifier for calculating for each of said the voxels one or more class probabilities of such voxel to contain a lesion of a particular type or being a non-lesion. The system also includes a lesion probability map generator for receiving the data produced by the voxel classifier and producing a probability intensity map for each of lesion types, in which one or more areas classified as lesion are highlighted; and an image display for displaying the output of the lesion probability map generator.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: December 10, 2024
    Assignee: UCB Biopharma SRL
    Inventors: Andrew Robert Carnell, Joeri Nicolaes
  • Patent number: 12091450
    Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: September 17, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: David Paul Humphreys, Ralph Adams, James Heads, Shirley Jane Peters
  • Patent number: 12077796
    Abstract: The present invention relates to the use of limited amounts of cysteine and tryptophan in the cell culture medium during production of recombinant proteins, and in particular antibodies. Proteins and antibodies produced under such controlled conditions exhibit reduced heterogeneity, in particular reduced charge variants heterogeneity.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: September 3, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Bassem Ben Yahia, Laetitia Malphettes, Nadine Kochanowski, Gill Renner, Sandrine Durran, Andrew Jeffrey Yates
  • Patent number: 12055549
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: August 6, 2024
    Assignees: UCB BIOPHARMA SRL, SANOFI
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Tracy Lynn Arakaki, Daniel John Lightwood, Rebecca Jayne Munro
  • Patent number: 12054559
    Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: August 6, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Thomas Allen Ceska, Anna Marie Davies, Alistair James Henry, Xiaofeng Liu, James Michael McDonnell, Brian John Sutton, Marta Katarzyna Westwood
  • Patent number: 12018021
    Abstract: Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: June 25, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Pfrafulkumar Tulshibhai Chovatia, Rickki Lee Connelly, Richard Jeremy Franklin, Gregory William Haslett, Alistair James Henry, James Madden, Judi Charlotte Neuss, Timothy John Norman, Oliver Philps, William Ross Pitt, Konstantinos Rampalakos, Matthew Duncan Selby, Selvaratnam Suganthan, Giancarlo Trani, Zhaoning Zhu
  • Patent number: 12006316
    Abstract: The invention relates to 9H-pyrrolo-dipyridine derivatives of formula I, processes for preparing them, pharmaceutical compositions containing them and their use as radiopharmaceuticals in particular as imaging agents for the detection of Tau aggregates.
    Type: Grant
    Filed: March 21, 2022
    Date of Patent: June 11, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Joel Mercier, Laurent Provins, Celine Vermeiren, Yogesh Anil Sabnis
  • Patent number: 11999772
    Abstract: The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: June 4, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Terence Seward Baker, Xiaofeng Liu
  • Patent number: 11975046
    Abstract: The present invention relates to methods for the treatment of fibrosis. The invention discloses new research which demonstrates that interferon-lambda has directly acting anti-fibrotic effects both in vitro and in vivo and may be used to provide effective new therapies for the treatment of multiple types of fibrosis.
    Type: Grant
    Filed: June 29, 2023
    Date of Patent: May 7, 2024
    Assignees: UCB BIOPHARMA SRL, FIVE PRIME THERAPEUTICS, INC.
    Inventors: Timothy Scott Johnson, Breda Twomey, Janine Powers, Danielle E. Kellar
  • Patent number: 11942188
    Abstract: Methods and associated apparatus involving designing a ligand ab initio that will bind to a binding site of a macromolecular target, or of identifying a modification to a ligand for improving the affinity of the ligand to a binding site of a macromolecular target, comprising using information about non-bonding, intra-molecular or inter-molecular atom to atom contacts extracted from a database of biological macromolecules to identify favoured regions adjacent to the binding site for particular atom types and modifying a candidate ligand to increase the intersection between atoms of the candidate ligand and the favoured regions. One or more steps of the methods may be performed by a computer.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: March 26, 2024
    Assignee: UCB Biopharma SRL
    Inventors: Jiye Shi, Terence Seward Baker, Alastair David Griffiths Lawson, Xiaofeng Liu
  • Patent number: 11919950
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: March 5, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson
  • Patent number: 11912721
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: February 27, 2024
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm MacCoss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Patent number: 11905310
    Abstract: The present invention relates to a process for purification a protein comprising a semi-continuous chromatography step whereby the flow-through is collected and re-loaded onto the chromatography matrix.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: February 20, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventor: Michael Harry Rose
  • Patent number: 11884737
    Abstract: The present invention relates to a method of treating an autoimmune or inflammatory disease or a neurodegenerative disease with an antibody to CD154.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: January 30, 2024
    Assignees: UCB BIOPHARMA SRL, BIOGEN MA INC.
    Inventors: Ruth Oliver, Miren Zamacona
  • Publication number: 20240000893
    Abstract: The present invention relates to methods for the treatment of fibrosis. The invention discloses new research which demonstrates that interferon-lambda has directly acting anti-fibrotic effects both in vitro and in vivo and may be used to provide effective new therapies for the treatment of multiple types of fibrosis.
    Type: Application
    Filed: June 29, 2023
    Publication date: January 4, 2024
    Applicants: UCB BIOPHARMA SRL, FIVE PRIME THERAPEUTICS, INC.
    Inventors: Timothy Scott JOHNSON, Breda TWOMEY, Janine POWERS, Danielle E. KELLAR
  • Patent number: 11857625
    Abstract: The present invention relates to pharmaceutical compositions comprising from an antibody or a fragment thereof which binds IL-17A and IL-17F and a combination of glycine, acetate buffer at pH 4.6 to 5.5 and polysorbate 80.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: January 2, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sandrine Durran, Andrew Jeffrey Yates
  • Patent number: 11859203
    Abstract: The present invention relates to methods for reducing the heterogeneity of a population of recombinant proteins produced in cell culture, said methods comprising growing host cells producing a recombinant protein in a cell culture medium wherein the cell culture medium comprises one or more cysteine/cystine analogs.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: January 2, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Valentine Chevallier, Nadine Kochanowski, Laetitia Malphettes, Vincent Adolphe Carol Cool
  • Patent number: 11834514
    Abstract: The present invention provides method for increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises a) a thermal conversion step of holding the composition comprising the antibody molecule at a temperature in the range 30 to 60° C. for a period of at least 1 hour, wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: December 5, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild, Christopher John Le Page, Razwan Hanif
  • Patent number: RE50178
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: October 22, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage